Search research articles
Contact Us
Filters
Showing results (91-100 of 112) with videos related to
Page
of 12
Sort By:
Haematologica
|
December 9, 2017
Melphalan 140 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
Holger W Auner, Simona Iacobelli, Giulia Sbianchi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 18, 2018
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
Firoozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, et al.
British Journal of Haematology
|
July 14, 2020
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial
Graham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Blood
|
May 1, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
Jad Othman, Nicola Potter, Adam Ivey, et al.
Plos Medicine
|
January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
Graham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Nature Communications
|
August 8, 2022
Unified classification and risk-stratification in Acute Myeloid Leukemia
Yanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Haematologica
|
June 6, 2020
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood
|
November 14, 2025
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18
Steven Knapper, Laura W Dillon, Malavika Babu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 3, 2019
Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study
Neema P Mayor, James D Hayhurst, Thomas R Turner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 14, 2019
A reply to Hurley et al. regarding Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study
Neema P Mayor, James D Hayhurst, Thomas R Turner, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 112) with videos related to
Sort By:
Page
of 12
Haematologica
|
December 9, 2017
Melphalan 140 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
Holger W Auner, Simona Iacobelli, Giulia Sbianchi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 18, 2018
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
Firoozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, et al.
British Journal of Haematology
|
July 14, 2020
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial
Graham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Blood
|
May 1, 2024
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
Jad Othman, Nicola Potter, Adam Ivey, et al.
Plos Medicine
|
January 11, 2021
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
Graham H Jackson, Charlotte Pawlyn, David A Cairns, et al.
Nature Communications
|
August 8, 2022
Unified classification and risk-stratification in Acute Myeloid Leukemia
Yanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, et al.
Haematologica
|
June 6, 2020
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
Graham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood
|
November 14, 2025
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18
Steven Knapper, Laura W Dillon, Malavika Babu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 3, 2019
Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study
Neema P Mayor, James D Hayhurst, Thomas R Turner, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 14, 2019
A reply to Hurley et al. regarding Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study
Neema P Mayor, James D Hayhurst, Thomas R Turner, et al.
Page
of 12